Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Alzheimer’s is a big market, no doubt. But what

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 155585
(Total Views: 696)
Posted On: 07/26/2020 2:43:41 PM
Posted By: Alekos
Re: ClosetInvestor #45005
Alzheimer’s is a big market, no doubt. But what I’m thinking is: if Leronlimab doesn’t get approved for Covid, when the drug is clearly outperforming everything else available, or if it gets approved but this somehow doesn’t translate to huge revenue for the company (because of supply issues or because of mysteriously low demand or for whatever reason) then how can we be optimistic about any other indication?
No other indication is going to put more pressure on government and FDA than Covid. If Covid doesn’t work out for us then...

Covid not working for us doesn’t mean that the drug will be any less efficacious towards all other indications. But what it would mean is that the company isn’t able to push the drug forward (whether it be cause we’re being blocked by greater forces or because the leadership is incapable, I don’t really care why). The truth of the matter is that while progressing the drug is taking us so much time for us, BP is moving much faster, and so is science in general. Zero CTCs is impressive but there’s quite a few drugs showing similar responses in early cancer trials. So even though we are currently ahead in terms of efficacy, there’s certainly no guarantee that will be the case in 2-3 years from now. IMO that’s most definitely the timeline we’re looking at.

Leronlimab is king. But that’s half of the game. The other half is leadership. I pray that NP proves me wrong, and that I’m wrong in criticizing him.


(1)
(2)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us